Welcome to our dedicated page for Omeros SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
Omeros Corp director Thomas J. Cable executed an options exercise-and-sale transaction involving 7,500 shares of common stock. He exercised stock options to acquire 7,500 shares at $10.84 per share, then sold 7,500 shares in open-market trades at a weighted average price of $11.6052 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on June 14, 2024, with the trading schedule set at that time. Following these transactions, Cable directly holds 35,067 shares of Omeros common stock. The options exercised were scheduled to expire on June 9, 2026, and the sale trades ranged in price from $11.46 to $11.93 per share.
Omeros Corporation reported a sharp turnaround in Q1 2026, posting net income of $56.1 million versus a $33.5 million loss a year earlier. The improvement was largely due to a $73.1 million non-cash gain from remeasuring the embedded derivative on its 2029 convertible notes.
Product sales reached $9.9 million following the January 2026 U.S. launch of YARTEMLEA for TA-TMA, while research and development spending declined to $13.4 million from $23.8 million. Operating cash flow remained negative at $14.5 million, but Omeros held $1.9 million in cash and $133.4 million in short-term investments as of March 31, 2026.
The balance sheet shows a shareholders’ deficit of $63.3 million, improved from $121.2 million at year-end 2025, influenced by the zaltenibart sale and debt actions. The company also continues to recognize income from OMIDRIA royalties and retains significant potential milestones and royalties from its APLA with Novo Nordisk.
Omeros Corporation reported a strong turnaround in first-quarter 2026 results, driven by the U.S. launch of YARTEMLEA. Net income was $56.1 million, or $0.78 per basic share, compared with a net loss of $33.5 million, or $0.58 per share, a year earlier.
Results include a non-cash gain of $73.1 million from marking to market embedded derivatives on 2029 convertible notes; excluding this, non-GAAP adjusted net loss was $17.1 million, or $0.24 per share. YARTEMLEA, launched in January 2026, generated gross product sales of $11.1 million and net sales of $9.9 million in the quarter.
At March 31, 2026, cash and short-term investments totaled $135.3 million. Omeros repaid the remaining $17.1 million principal on its 2026 notes and now has $70.8 million of 2029 notes outstanding. Total operating expenses declined to $27.3 million from $35.0 million a year earlier as R&D spending fell after the Novo Nordisk zaltenibart transaction.
Omeros Corporation is asking shareholders to vote at its fully virtual 2026 annual meeting on June 18, 2026 at 10:00 a.m. Pacific time. Holders of 72,168,330 common shares outstanding as of April 17, 2026 can vote online, by phone, by mail, or during the webcast.
Shareholders will elect three Class II directors, cast an advisory "say‑on‑pay" vote on executive compensation, approve an amended and restated omnibus incentive compensation plan, and ratify Ernst & Young LLP as auditor for 2026. The board recommends voting FOR all proposals.
The filing highlights Omeros’ governance structure, including a combined CEO/chair with a lead independent director, independent board committees, restrictions on hedging and pledging company stock, and a compensation clawback policy tied to accounting restatements. It also details 2025 pay, including total CEO compensation of $4.18 million, primarily driven by stock option awards that vest over time.
Ingalls & Snyder, LLC reports beneficial ownership of 3,466,268 shares of OMEROS CORP common stock, representing 4.8% of the class. The filing states the reported share count includes shares held in advisory accounts and assumes conversion of $550,000 principal of Omeros 5.25% due 2/15/26. The filer reports shared dispositive power for all 3,466,268 shares and discloses the filing as an amendment (No. 14).
Omeros Corporation reports its annual results and outlines a major strategic shift toward complement-mediated diseases, oncology, and infectious disease therapies. Its lead product, YARTEMLEA (narsoplimab-wuug), became the first FDA‑approved treatment for TA‑TMA on December 23, 2025, with U.S. sales starting in January 2026.
Omeros also completed an Asset Purchase and License Agreement with Novo Nordisk, granting global rights to MASP‑3 antibody zaltenibart for an upfront $240.0 million, up to $1.8 billion in potential milestones, plus tiered royalties. The company maintains a diversified pipeline, including MASP‑2 programs OMS1029 and additional indications for narsoplimab, PDE7 program OMS527 for addiction and movement disorders, the OncotoX‑AML oncology candidate approaching IND‑enabling completion, and the T‑CAT infectious disease platform targeting multidrug‑resistant organisms.
Omeros Corporation reported a sharp turnaround in late 2025, driven by a major asset sale and its first U.S. drug approval. Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, a year earlier. For full-year 2025, net loss narrowed to $3.4 million, or $0.05 per share, from a $156.8 million loss in 2024.
Results reflected a $237.6 million net gain from the zaltenibart transaction with Novo Nordisk and a $136.0 million non-cash loss from marking embedded derivatives on the company’s 2029 Notes and Term Loan. Excluding this non-cash item, non-GAAP adjusted net income was $222.5 million, or $3.14 per share, for the quarter and $133.4 million, or $2.10 per share, for the year.
At December 31, 2025, Omeros held $171.8 million in cash and short-term investments and had $87.9 million in aggregate principal debt, down from $164.9 million a year earlier after using Novo Nordisk proceeds to repay its senior secured term loan and 2026 convertible notes. The company also achieved FDA approval and U.S. launch of YARTEMLEA for TA-TMA, began commercial sales in January 2026, and highlighted progress across its oncology, PDE7, and T-CAT infectious disease programs.
Omeros Corp ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A describing an internal realignment that disaggregates certain subsidiaries and business divisions. The filing states amount beneficially owned: 0 and percent of class: 0% following the realignment, with no sole or shared voting or dispositive power reported. The filing explains that subsidiaries will report separately under SEC Release No. 34-39538.